Janssen Showcases Phase 2 Nipocalimab (M281) Data in Adults with Generalized Myasthenia Gravis (gMG) at the 2021 American Academy of Neurology Virtual Meeting
Full results from the Vivacity-MG study to be presented for the first time during an oral presentation
News provided by
Share this article
Share this article
TITUSVILLE, N.J., April 16, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the full results from the Phase 2 Vivacity-MG study of the investigational compound, nipocalimab (M281), in generalized myasthenia gravis (gMG)–a chronic, autoimmune neuromuscular disease. The data will be featured as part of an oral presentation at the American Academy of Neurology (AAN) Virtual Meeting taking place April 17-22, 2021.
of
LEXINGTON, Ky. (April 16, 2021) Dr. Larry Goldstein, chair of the University of Kentucky Department of Neurology, has been elected to serve on the board of directors of The American Academy of Neurology (AAN). Goldstein also is co-director of the Kentucky Neuroscience Institute, co-director of the UK Neuroscience Research Priority Area and interim director of the UK-Norton Healthcare Stroke Care Network.
Goldstein received his bachelor s degree in 1977 from Brandeis University and his medical degree from Mount Sinai School of Medicine in 1981. His subsequent professional training included an internship and neurology residency at Mount Sinai Medical Center, New York (1981-1985) and a research fellowship in cerebrovascular disease at Duke University (1985-1987). Goldstein advanced at Duke University to the rank of professor of neurology and director of the Duke Stroke Center prior to moving to the University of Kentucky in 2015.
Share this article
Share this article
MINNEAPOLIS, April 16, 2021 /PRNewswire/ A preliminary study suggests that Black people who have autoimmune neurologic diseases, multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), may respond differently than white people to a common therapy meant to modulate the immune system. The research will be presented at the American Academy of Neurology s 73rd Annual Meeting being held virtually April 17 to 22, 2021.
The people in this study were given anti-CD20 infusion therapies, which are often used to treat autoimmune diseases such as MS and neuromyelitis optica spectrum disorder, which is a relapsing inflammatory disorder of the optic nerve, spinal cord and brain. The goal of this treatment, called B-cell depletion therapy, is to destroy B-cells in blood circulation. B-cells are partly responsible for the abnormal autoimmune responses in people with MS and NMOSD.
(diroximel fumarate) reinforce the treatment’s positive gastrointestinal tolerability profile
Biogen advances leading research to help inform future patient management including new information on the clinical profile of extended interval dosing with natalizumab
CAMBRIDGE, Mass., April 16, 2021 (GLOBE NEWSWIRE) Biogen Inc. (Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies to be presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting, April 17-22. The presentations include data on quality of life benefits and analyses of extended interval dosing (EID) with TYSABRI
® (natalizumab) as well as new real-world experience data from VUMERITY
® (diroximel fumarate). The research adds to the vast clinical knowledge Biogen continues to advance as part of its commitment to the care of people living with MS.
UCB showcases new research at the 73rd American Academy of Neurology Annual Meeting to demonstrate broad neurology leadership and future portfolio
- UCB reinforces commitment to delivering increased patient value by presenting latest research findings in epilepsy, myasthenia gravis, and Parkinson s disease
- Nine scientific presentations illustrate UCB s dedication to neurology and highlight the importance of gathering patient insight to transform patient experience
- UCB will also host a virtual symposium to discuss the clinical features of rare autoimmune neuromuscular diseases such as generalized myasthenia gravis, held on Tuesday, April 20, 09:00 - 10:00 ET
News provided by
Share this article
Share this article